Last reviewed · How we verify
Ranibizumab (Lucentis)
Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye.
Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye. Used for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.
At a glance
| Generic name | Ranibizumab (Lucentis) |
|---|---|
| Also known as | Lucentis, NDC # 50242-0080-01, Brand Name is Lucentis, ranibizumab, Ranibizumab (anti-VEGF agent), Lucentis = ranibizumab |
| Sponsor | Greater Houston Retina Research |
| Drug class | VEGF-A inhibitor (monoclonal antibody fragment) |
| Target | VEGF-A (Vascular Endothelial Growth Factor A) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Ranibizumab is a recombinant humanized monoclonal antibody fragment (Fab) that specifically targets and neutralizes VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. By blocking VEGF-A signaling, it prevents the formation of abnormal blood vessels and reduces fluid leakage, thereby slowing or halting vision loss in retinal conditions. It is administered via intravitreal injection directly into the eye to achieve high local concentrations.
Approved indications
- Neovascular (wet) age-related macular degeneration
- Macular edema following retinal vein occlusion
- Diabetic macular edema
- Diabetic retinopathy
- Myopic choroidal neovascularization
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
- Retinal detachment
Key clinical trials
- Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (PHASE3)
- A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
- Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PHASE3)
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (PHASE4)
- A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME (PHASE3)
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE2)
- A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ranibizumab (Lucentis) CI brief — competitive landscape report
- Ranibizumab (Lucentis) updates RSS · CI watch RSS
- Greater Houston Retina Research portfolio CI